ZA96530B - Transdermal formulation - Google Patents

Transdermal formulation

Info

Publication number
ZA96530B
ZA96530B ZA96530A ZA96530A ZA96530B ZA 96530 B ZA96530 B ZA 96530B ZA 96530 A ZA96530 A ZA 96530A ZA 96530 A ZA96530 A ZA 96530A ZA 96530 B ZA96530 B ZA 96530B
Authority
ZA
South Africa
Prior art keywords
transdermal formulation
transdermal
formulation
Prior art date
Application number
ZA96530A
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Michael Horstmann
Harlan Edgar Shannon
Lisa Ann Shipley
Kirti Himatlal Valia
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA96530B publication Critical patent/ZA96530B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA96530A 1995-01-30 1996-01-22 Transdermal formulation ZA96530B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38047895A 1995-01-30 1995-01-30

Publications (1)

Publication Number Publication Date
ZA96530B true ZA96530B (en) 1997-07-23

Family

ID=23501315

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA96530A ZA96530B (en) 1995-01-30 1996-01-22 Transdermal formulation

Country Status (23)

Country Link
US (1) US5980933A (de)
EP (1) EP0723781A3 (de)
JP (1) JPH10513181A (de)
KR (1) KR19980701730A (de)
AR (1) AR001790A1 (de)
AU (1) AU709379B2 (de)
BR (1) BR9600216A (de)
CA (1) CA2210711A1 (de)
CO (1) CO4700420A1 (de)
CZ (1) CZ240297A3 (de)
EA (1) EA001083B1 (de)
HU (1) HUP9800832A3 (de)
IL (1) IL116895A (de)
NO (1) NO973471L (de)
NZ (1) NZ301197A (de)
PE (1) PE17397A1 (de)
PL (1) PL321686A1 (de)
RO (1) RO117146B1 (de)
TR (1) TR199700711T1 (de)
TW (1) TW304167B (de)
WO (1) WO1996023463A1 (de)
YU (1) YU5196A (de)
ZA (1) ZA96530B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0821956A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung disruptiver Verhaltensstörungen
EP0821954A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung von geistiger Zurückgebliebenheit
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
JP5106715B2 (ja) * 1999-09-24 2012-12-26 アルロン・ジャパン株式会社 Ｌ−アスコルビン酸、ｌ−アスコルビン酸誘導体の皮膚真皮層への放出方法に使用するための組成物
US7691404B2 (en) * 2000-11-06 2010-04-06 Samyang Corporation Transdermal delivery system of diclofenac with improved water absorbability and adhesion properties
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
DE102005050431A1 (de) * 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
US20070259859A1 (en) * 2006-05-04 2007-11-08 De Bruin Natasja M W J Muscarinic agonists to treat impulse control disorders
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US8846740B2 (en) 2011-01-04 2014-09-30 Biological Responsibility, Llc Biotherapeutics for the treatment of infectious diseases
EP3265067A4 (de) * 2015-03-06 2018-09-12 Chase Pharmaceuticals Corporation Transdermale oxybutynin-xanomelin-therapiesystemkombinationen
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
MY102980A (en) * 1986-10-31 1993-03-31 Pfizer Transdermal flux enhancing compositions
DE3871464D1 (de) * 1987-08-28 1992-07-02 Lilly Co Eli Die permeation verbessernde zusammensetzung.
IT1233860B (it) * 1988-02-08 1992-04-21 Isf Spa Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa
DE3843239C1 (de) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions

Also Published As

Publication number Publication date
RO117146B1 (ro) 2001-11-30
TW304167B (de) 1997-05-01
EP0723781A3 (de) 1996-08-07
JPH10513181A (ja) 1998-12-15
PE17397A1 (es) 1997-05-21
CZ240297A3 (cs) 1998-04-15
HUP9800832A2 (hu) 1999-01-28
PL321686A1 (en) 1997-12-22
IL116895A0 (en) 1996-05-14
KR19980701730A (ko) 1998-06-25
BR9600216A (pt) 1998-01-06
CO4700420A1 (es) 1998-12-29
EA001083B1 (ru) 2000-10-30
EP0723781A2 (de) 1996-07-31
TR199700711T1 (xx) 1998-01-21
EA199700151A1 (ru) 1997-12-30
IL116895A (en) 2000-08-31
AR001790A1 (es) 1997-12-10
NO973471D0 (no) 1997-07-28
YU5196A (sh) 1998-08-14
US5980933A (en) 1999-11-09
WO1996023463A1 (en) 1996-08-08
AU709379B2 (en) 1999-08-26
AU4656596A (en) 1996-08-21
MX9705723A (es) 1997-11-29
NO973471L (no) 1997-09-19
CA2210711A1 (en) 1996-08-08
NZ301197A (en) 1999-09-29
HUP9800832A3 (en) 2000-07-28

Similar Documents

Publication Publication Date Title
GB9514842D0 (en) Novel formulation
EP0846088A4 (de) Zementformulierung
GB9519363D0 (en) Pharmaceutical formulation
GB9402029D0 (en) Novel formulation
EP0862431A4 (de) Pharmazeutische formulierung
HUP9800832A3 (en) Transdermal formulation
IL116997A0 (en) Transdermal formulation
IL116999A0 (en) Transdermal formulation
GB9523566D0 (en) Pharmaceutical formulation
GB2307857B (en) An effervescent formulation
GB9615628D0 (en) Formulation
AU6708996A (en) Transdermal nitrate formulation
HU9602732D0 (en) Lanperisone formulation
ZA96797B (en) Transdermal formulation.
GB9404989D0 (en) Lipomimetric formulation
GB9508684D0 (en) Novel formulation
AUPN493095A0 (en) Transdermal composition
GB9412642D0 (en) Formulation
GB9412641D0 (en) Formulation
GB9416500D0 (en) Formulation
ZA952272B (en) Formulation
GB9423416D0 (en) Formulation
GB9525386D0 (en) Pharmaceutical formulation
GB9502786D0 (en) Pharmaceutical formulation
GB9509559D0 (en) Gel formulation